I
Ikonisys
Providing fully-automated slide handling, slide scanning, and real-time image capture and analysis for microscopy
About Ikonisys
Ikonisys Inc. operates in the healthcare diagnostics sector, focusing on the development and marketing of advanced cancer diagnostic tools. The company specializes in cell-based diagnostics, utilizing its proprietary Digital Microscope technology to deliver highly accurate and reliable detection of rare cancer cells. Ikonisys collaborates with Empire Genomics to enhance its FISH probes, optimizing results for various cancer detection tests. The company's products are designed to meet the stringent requirements of healthcare providers and the needs of patients, ensuring high-quality medical diagnostics. Ikonisys serves healthcare professionals and institutions, providing them with cutting-edge tools for cancer diagnosis. The business model revolves around the sale and distribution of its diagnostic products, generating revenue through product sales and strategic collaborations. Led by CEO Mario Crovetto, who has extensive experience in the healthcare sector, Ikonisys is committed to maintaining an effective Quality Management System, ensuring that all employees adhere to high standards in their work.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1999
- Headquarters
- Paris, France
- Listing
- IPO 2021
- Employees
- 39
- Open positions
- None listed
- Dealroom signal
- 38.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Hard Tech, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
- Business model
- Manufacturing
- Client focus
- b2c
- Investment activity
- 1 company, latest Nov 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Nov 2024 | $220K | — | Undisclosed | ↗ |
| PRIVATE PLACEMENT VCOther financing | Jul 2024 | $275K | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $1.1M | 0% |
| 2025 | $1.1M | 0% |
| 2024 | $1.1M | +125.4% |
| 2023 | $493K | — |
Growth signals
Latest recorded traffic for Ikonisys is 1.8K monthly website visits, up 958.8% over the last three months. Ikonisys's team declined 2.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later7 investors entered at this stage
Trevi Health Ventures
New Science Ventures- LMLakeview Capital Management
- WGWGI Group
- SISaint Simeon Marketing and Investments
Negma Group- LLLPE II LP
Other known investors1 additional known investor
- CPCambria Equity Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ikonisys on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ikonisys’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.